Oral bisphosphonates in polyostotic fibrous dysplasia

Indian Pediatrics

Volumn 40, Issue 9, 2003, Pages 894-896

  Khadilkar, V V ^a   Khadilkar, A V ^b   Maskati, G B ^b  

^a JEHANGIR HOSPITAL   (India)

^b NONE

Author keywords

Bisohbsphonates; Polyostotic fibrous dysplasia

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ALBRIGHT SYNDROME; ARTICLE; BONE DENSITY; BONE MINERAL; CASE REPORT; DRUG MECHANISM; HUMAN; MALE; OSTEOCLAST; OSTEOLYSIS; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ALENDRONATE; BONE DENSITY; CHILD, PRESCHOOL; FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS; MALE;

EID: 0141633714     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Krane S. Paget's disease of the bone: In: Isselbacher KJ, Braundwald E, Wilson JD, Martin JB, Fauci AS, Dennis LK, (Eds). Harrison's Principles of Internal Medicine, 13th edn. New York: McGraw-Hill Inc 1994; 2190-2192.
2. Chapurlat RD, Meunier PJ. Fibrous dysplasia of bone. Baillieres Best Res Clin Rheumatol 2000; 14:385-398.
3. Devogelaer JP. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 2000; 12:331-335.
4. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 39:947-952.
5. Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 2001. 69: 94-101.